Leerink Partners Upgrades Amgen to Outperform, Raises Price Target to $318
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst David Risinger has upgraded Amgen (NASDAQ:AMGN) from Market Perform to Outperform and raised the price target from $267 to $318.

October 11, 2023 | 6:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's stock rating has been upgraded to Outperform by Leerink Partners, with a raised price target of $318.
The upgrade from Market Perform to Outperform by Leerink Partners indicates a positive outlook for Amgen. The raised price target from $267 to $318 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100